Long-Term CRYSVITA® ▼ (burosumab) Treatment Reduces the Burden of Disease in Adults With X-Linked Hypophosphataemia (XLH), a Rare Genetic Metabolic Bone Disease
Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin) today announced the publication of new data highlighting the sustained benefits of treatment with CRYSVITA (burosumab) in adults with X-linked hypophosphataemia (XLH), a rare genetic metabolic bone disease.
- Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin) today announced the publication of new data highlighting the sustained benefits of treatment with CRYSVITA (burosumab) in adults with X-linked hypophosphataemia (XLH), a rare genetic metabolic bone disease.
- The data show that adults with XLH experience substantial pain, stiffness, fatigue and impairment in physical and ambulatory function.
- Burosumab treatment has previously been shown to improve phosphate homeostasis in adult XLH patients, compared to placebo.
- One of our areas of focus is to generate new data that improve our understanding of how best to manage and treat XLH.